Arrowhead CEO Anzalone Sells 85,000 Shares for $5.44 Million
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 11 2026
0mins
Source: NASDAQ.COM
- Insider Sale: Arrowhead Pharmaceuticals CEO Christopher Anzalone sold 85,000 shares on December 17, 2025, for approximately $5.44 million, reducing his direct holdings to 3,831,957 shares, which reflects his ongoing tax planning strategy.
- Market Reaction: This stock sale occurred against the backdrop of Arrowhead's share price surge following FDA approval of its first drug, Redemplo, which reached a 52-week high of $76.76 on January 6, 2026, indicating strong market optimism about the company's prospects.
- Holding Value: Post-transaction, Anzalone's remaining shares are valued at $248,310,813.60, underscoring his significant financial stake in the company, although the sale may raise some market concerns.
- Strategic Implications: The sale did not trigger panic in the market but was viewed as a prudent tax planning move, demonstrating executive confidence in the company's future while highlighting Arrowhead's competitive edge in RNA interference technology.
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARWR is 75.50 USD with a low forecast of 35.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 69.590
Low
35.00
Averages
75.50
High
100.00
Current: 69.590
Low
35.00
Averages
75.50
High
100.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
